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Abstract
Objective: To determine the prevalence of significant intracranial injury among adults with blunt 
head trauma who are on preinjury anticoagulant or antiplatelet medications.
Methods: This was a multicenter, prospective, observational, study conducted from December 
2007 to December 2015. Patients were enrolled in three emergency departments in the United 
States. Adults with blunt head trauma who underwent neuroimaging in the emergency department 
were included. Use of preinjury aspirin, clopidogrel, warfarin was recorded. Data on direct oral 
anticoagulants was not specifically recorded. The primary outcome was prevalence of significant 
intracranial injury on neuroimaging. The secondary outcome was receipt of neurosurgical 
intervention.
Results: Among 9,070 patients enrolled in this study, the median age was 53.8 years (IQR: 34.7 
to 74.3) and 60.7% were male. A total of 1,323 patients (14.6%) were taking antiplatelet 
medications or warfarin, including 635 taking aspirin alone, 109 clopidogrel alone, and 406 
warfarin alone. As compared to patients without any coagulopathy, the relative risk of significant 
intracranial injury was 1.29 (95% CI: 0.88, 1.87) for patients taking aspirin alone, 0.75 (95% CI: 
0.24, 2.30) for those taking clopidogrel alone, and 1.88 (95% CI: 1.28, 2.75) taking warfarin alone. 
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The relative risk of significant intracranial injury was 2.88 (95% CI: 1.53, 5.42) for patients taking 
aspirin and clopidogrel in combination.
Conclusions: Patients on preinjury warfarin or a combination of aspirin and clopidogrel were at 
increased risk for significant intracranial injury, but not those on aspirin alone. Clinicians should 
have a low threshold for neuroimaging when evaluating patients on warfarin or on a combination 
of aspirin and clopidogrel.
Introduction
Background
Antiplatelet and anticoagulant medications are commonly used in North America for a 
variety of indications.1–5 It is widely believed that preinjury use of these medications 
increases the risk of traumatic intracranial injury and worsens clinical outcomes after blunt 
head trauma.6–9 This belief is based largely on biological plausibility and retrospective 
cohort studies.10,11 Current guidelines from the American College of Emergency Physicians 
(ACEP) and the National Institute for Health and Care Excellence (NICE) on the initial 
management of traumatic brain injury recommend a non-contrast head computed 
tomography (CT) scan in all patients with coagulopathy.12,13 However, these guidelines do 
not provide guidance for individual medications such as aspirin or other antiplatelet agents. 
Both cite a paucity of evidence on this topic partly due to exclusion of anticoagulated 
patients from studies conducted to derive clinical prediction instruments for blunt head 
trauma, e.g. the Canadian Head CT rule and the New Orleans Criteria.14,15 Other attempts to 
assess the increased risk of intracranial injury associated with coagulopathy have included 
this as one variable without separating different subtypes of coagulopathy based on 
individual medications.16 Contrary to common belief, anticoagulant/antiplatelet use was not 
shown to be predictive of traumatic intracranial hemorrhage after adjusted analysis in more 
recent, prospective studies.17,18
Importance
Given how commonly patients with blunt head trauma present to the emergency department 
(ED) and how often they are taking anticoagulant or antiplatelet medication, it is important 
to know what the actual magnitude of this increased risk is, if any, for specific agents such as 
warfarin, aspirin, and clopidogrel.
Goals of This Investigation
Our objective was to determine the prevalence of significant intracranial injury and 
neurosurgical intervention after acute blunt head trauma in ED patients on specific preinjury 
anticoagulant or antiplatelet medications, as compared to those without any coagulopathy.
Methods
Study Design and Setting
This was a pre-planned secondary analysis of data from a large, multicenter, observational 
study that was conducted to derive and validate a clinical decision instrument to predict 
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significant intracranial injury among patients presenting with blunt head trauma.19 Two of 
the participating emergency departments (EDs) were located at level 1 urban academic 
trauma centers, and one was a level 2 suburban community trauma center in California. We 
obtained institutional review board approval from all participating centers.
Selection of Participants
All adults (age 18 and over) acute blunt head trauma patients for whom head CT scanning 
was ordered between December 2007 and December 2015 were eligible for inclusion. 
Patients with a delayed presentation (> 24 hours after injury), with penetrating trauma, or 
those with known intracranial injuries who were transferred to a participating center were 
excluded. There were no exclusions based on Glasgow Coma Scale (GCS) score. The 
decision to obtain CT imaging was based on the clinical judgment of the treating physician 
and was not dictated by study protocol. Other methodological details have been published 
previously.20
Data Collection and Management
Research assistants were trained to approach the treating clinicians and collect demographic, 
clinical, and medication information on each patient using a standardized data collection 
form prior to CT. (eFigure 1). For those deemed unstable, determined by the clinician as any 
patient who might be harmed by a delay in imaging, data collection was bypassed and 
immediate imaging was obtained, prior to criterion assessment. Clinicians were asked to 
complete assessments of the study criteria as soon as possible prior to imaging results 
becoming available. Specifically, clinicians were queried as to whether the patient in 
question was taking aspirin, clopidogrel, warfarin, or had any other coagulopathy. “Other 
coagulopathy” was not strictly defined and could have included factors such as other 
anticoagulant medications (e.g. heparin) or medical conditions (e.g. severe hepatic 
dysfunction, hemophilia). Possible responses were “yes”, “no”, or “unknown”. Clinical 
variables included in the NEXUS-II16 and Canadian Head CT Rule14 were prospectively 
collected as well, including significant vomiting, dangerous mechanism of injury (defined as 
pedestrian struck by motor vehicle, occupant ejected from motor vehicle, fall from height >3 
feet or five stairs), GCS score of 15, neurologic deficit, amnesia, and level of alertness.
Outcomes
Our primary outcome measure was the presence of significant intracranial injury (ICI) on 
neuroimaging studies. The definition of significant ICI was based on prior work involving 
experts in neurosurgery, neuroradiology and emergency medicine.21 Isolated linear or basilar 
skull fractures, single small cerebral contusions, and coincidental or congenital 
abnormalities were not considered to represent a significant ICI. A list of significant ICIs is 
shown in eFigure 2 and includes injuries such as subarachnoid hemorrhage, subdural and 
epidural hematoma, depressed or complex skull fracture, intracerebral hematoma, diffuse 
cerebral edema, intraventricular hemorrhage, cerebral contusions >2 cm in diameter, diffuse 
cerebral edema, pneumocephalus, and diastasis of the skull. Our secondary outcome was the 
need for neurosurgical intervention, defined in previous studies specifically as 1) death due 
to head injury, 2) craniotomy, 3) elevation of skull fracture, 4) intubation related to head 
injury, or 5) intracranial pressure monitoring, within 7 days of head injury.14
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Copies of all final radiology reports were collected and abstracted by trained research 
assistants to determine the presence or absence of significant ICIs. The diagnosis of 
significant ICI was based on final radiologic interpretations of all imaging studies as read by 
board-certified radiologists. Investigators determined final injury classification while blinded 
to information about clinical and medication variables. ICI and neurosurgical intervention 
data was collated with clinical data to form the final study database.
Since we only enrolled patients who underwent neuroimaging, it possible that significant 
injuries were missed among the unimaged patients. To address this potential verification 
bias, we conducted 3-month follow-up interviews on 368 consecutive blunt head injury 
patients who presented between July 2011 and March 2015 at one study center. Follow-up 
interviews assessed whether each patient had received neuroimaging, a diagnosis of ICI, or a 
neurosurgical intervention at another facility during a subsequent visit. We also reviewed 
case logs and trauma logs to identify any instances of significant ICIs or injuries requiring 
neurosurgical intervention that occurred among blunt head trauma patients who were seen 
but not imaged on their initial presentation.
Statistical Analysis
We performed all analyses using SAS (version 9.3, SAS Institute Inc., Cary, NC). Patient 
characteristics are reported using descriptive statistics reported as frequencies, medians, and 
interquartile ranges (IQR). Our sample size calculation was based on the number of imaged 
head trauma patients estimated to be taking aspirin (~5%). Using the following equation to 
calculate the lower confidence internal of a proportion: 0.99 = N/(N+F 0.05,2,2N), we 
derived that our necessary sample size would be 370 patients undergoing head CT imaging 
on preinjury aspirin. Thus, we needed to enroll 20 × 370 = 7,400 patients overall. Our final 
sample size of 9,070 exceeded this number. We did not specifically power the study to 
examine the effects of warfarin or clopidogrel.
We compared the prevalence of primary and secondary outcome measures across specific 
anticoagulant or antiplatelet medication groups including: aspirin alone, clopidogrel alone, 
warfarin alone, aspirin and clopidogrel combined, aspirin and warfarin combined, and “other 
coagulopathy”. Prevalences were compared using relative risks (RR) with 95% confidence 
intervals (CI). We then performed a subgroup analysis with the following subgroups: 
patients 65 years old or older, patients with significant comorbidity, patients with dangerous 
mechanism of injury, patients with GCS score of 15, and patients with a normal level of 
alertness. We also performed a sensitivity analysis using “any traumatic injury” as the 
primary outcome, which included findings such as a small, solitary contusion, isolated linear 
skull fracture, and localized subarachnoid blood less than 1mm thick; all in neurologically 
intact patients. Responses of “unknown” were treated as missing data, and no data 
imputation was performed.
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Results
Characteristics of study subjects
Over the 8-year study period, we prospectively enrolled 9,070 adult patients presenting with 
blunt head trauma undergoing CT scanning of the head (See Figure 1). Median age was 53.8 
years (range: 18 to 104, IQR=34.7 to 73.5) and 39% were female. Overall, 1,323 (14.6%) 
were taking at least one antiplatelet or anticoagulant medication. Most patients (77.5%) had 
a GCS score of 15, a dangerous mechanism of injury (57.6%) and a normal level of alertness 
(72.3%). Further clinical and demographic data are presented in Table 1. Overall, there were 
532 (5.9%) patients with a significant ICI and 297 (3.3%) patients required neurosurgical 
intervention. Of the 1,323 patients taking antiplatelet or anticoagulant medications, 635 
(7.0%) were on aspirin alone, 109 (1.2%) were on clopidogrel alone, 406 (4.5%) on warfarin 
alone, 85 (0.9%) were on both aspirin and clopidogrel concurrently, and 42 (0.5%) on 
aspirin and warfarin concurrently. Further coagulopathy data is presented in eTable 1. Of the 
368 consecutive patients with blunt head trauma who did not undergo initial neuroimaging, 
zero reported evidence of a subsequently diagnosed ICI. Review of trauma logs also 
revealed no evidence of missed ICIs.
Main Results
Among patients taking aspirin alone, 30 of 635 had a significant ICI (4.7%, 95%CI: 3.3, 
6.6%); among those taking clopidogrel alone, 3 of 109 had a significant ICI (2.8%, 95%CI: 
0.7, 7.0%); and among those taking warfarin alone 28 of 406 had a significant ICI (6.9%, 
95%CI: 4.7, 9.6%). The prevalence of significant ICI among patients not on any of the above 
agents, and without any other coagulopathy (labeled “No Coagulopathy”) was 210 of 5,715 
(3.7%, 95%CI: 3.2, 4.2%). The prevalence of significant ICI among patients taking aspirin 
alone or clopidogrel alonewas not significantly different than among those with no 
coagulopathy (See Table 2). There was a statistically significant increase in risk of 
significant ICI in patients taking warfarin alone (RR=1.88, 95%CI: 1.28, 2.75), as well as 
aspirin and clopidogrel combination therapy (RR=2.88, 95%CI: 1.53, 5.42). Further data 
regarding the relative risk of significant ICI is presented in Table 2 and in Figure 2.
Among patients taking aspirin alone, 9 of 635 required a neurosurgical intervention (1.4%, 
95%CI: 0.7, 2.5%); among those taking clopidogrel alone, 1 of 109 required a neurosurgical 
intervention (0.9%, 95%CI: 0.1, 4.0%); and among those taking warfarin alone, 16 of 406 
required a neurosurgical intervention (3.9% 95%CI: 2.3, 6.1%). The prevalence of 
neurosurgical intervention among patients with no coagulopathy was 85 of 5715 (1.5%, 
95%CI: 1.2, 1.8%). The prevalence of neurosurgical intervention among patients taking 
aspirin alone or clopidogrel alone was not significantly different than among those with no 
coagulopathy. There was a statistically significant increase in risk of requiring a 
neurosurgical intervention in patients taking warfarin alone (RR=2.65, 95%CI: 1.57, 4.48) 
and in those taking aspirin and clopidogrel combined (RR=4.75, 95%CI: 2.13, 10.6). Further 
data regarding prevalence of neurosurgical intervention is presented in Table 2.
A sensitivity analysis using any traumatic injury as our primary outcome resulted in similar 
findings, with one notable exception. Aspirin and warfarin combination therapy was 
Probst et al. Page 5
Ann Emerg Med. Author manuscript; available in PMC 2021 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
associated with an increased relative risk of traumatic injury (RR=2.08, 95% CI: 1.05, 4.10). 
See Table 4 for more detail.
Our subgroup analysis revealed that in the subgroup of patients aged 65 years and older, 
none of the medications, as monotherapy or in combination, were statistically significantly 
associated with prevalence of significant ICI. Similar results were found in the subgroup of 
patients with a significant medical comorbidity, with one exception: patients on combination 
aspirin and clopidogrel were at higher relative risk for significant ICI (RR=2.44, 95% CI: 
1.05, 5.64). The increased risk of significant ICI found for patients taking warfarin alone 
persisted when analyzing the subgroups of patients with a dangerous mechanism, with a 
GCS of 15, or with a normal level of alertness.
Our subgroup analysis revealed that in the subgroup of patients aged 65 years and older, 
none of the medications were statistically significantly associated with an increase in 
neurosurgical intervention with one exception: patients on combination aspirin and 
clopidogrel were at higher relative risk for neurosurgical intervention (RR=2.94, 95% CI: 
1.28, 6.76). The increased risk of neurosurgical intervention found for patients taking 
warfarin persisted when analyzing the subgroups of patients with a dangerous mechanism, 
and with a GCS of 15, but not with a normal level of alertness. See Table 3 for further 
subgroup analyses.
Limitations
Our study has certain limitations. Firstly, we do not have specific data on all patients who 
presented to the study EDs with blunt head trauma but did not undergo neuroimaging. 
However, our follow-up data on a sample of these un-imaged patients suggest that the rate of 
missed significant ICI is very low if not near zero. Secondly, we do not have any data 
pertaining to rates of delayed intracranial hemorrhages, only data based on initial 
neuroimaging during the index visit. Thus, some of the patients in our study may have had 
significant ICIs discovered at a later time. Thirdly, we did not specifically collect data on the 
direct oral anticoagulants (DOACs), such as rivaroxaban, dabigatran, apixaban, since these 
agents were relatively rare at the commencement of our study. Recent clinical data suggests 
that the risk of bleeding and intracranial bleeding among patients taking these agents is no 
greater than the risk of bleeding for patients taking warfarin.22,23 Fourthly, we did not use 
laboratory analyses (e.g. international normalized ratio, platelet function tests) to verify 
whether patients were actually taking the antiplatelet or anticoagulant medications. This 
does mimic real world situations, however, in which clinicians must make imaging decision 
based on the history provided. Finally, a significant number of patients in our study (roughly 
one third) had “unknown” medication status limiting the sample size of those who were 
reportedly on the medications of interest. Despite our large sample size, there were a modest 
number of significant ICIs in the final dataset (n=532) and a relatively small number in each 
anticoagulation category.
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Discussion
In this large, prospective study examining the prevalence of significant ICI after blunt head 
trauma in patients on anticoagulant and antiplatelet medications, we found that patients on 
preinjury warfarin monotherapy were at significantly higher risk of both significant ICI and 
neurosurgical intervention as compared to those without any known coagulopathy (Table 2). 
This increased risk persisted in most, but not all, of our subgroup analyses (Table 3). 
Surprisingly, neither aspirin monotherapy, nor clopidogrel monotherapy, was associated with 
a significantly greater RR of significant ICI, although the point estimate of the RR was 
slightly greater than 1 in in the aspirin alone group. There are several possible explanations 
for such findings. For one, the antiplatelet effect of aspirin and clopidogrel, while conferring 
benefit for cardiovascular outcomes, may not actually affect platelet function enough to have 
clinically significant impact on risk of significant ICI. Alternatively, this lack of association 
may be explained by patients on antiplatelet agents having a lower threshold to seek care, 
and similarly, clinicians having a lower threshold to obtain neuroimaging after head trauma. 
This would increase the number of otherwise “lower risk” patients presenting to the ED and 
undergoing neuroimaging, and thus deflate the prevalence of significant ICI. However, in 
our subgroup analyses, examining only the subgroup of patients with a dangerous 
mechanism, we found the same results, i.e. a non-significant trend towards increased risk of 
significant ICI in patients with individual preinjury antiplatelet medication use. The lack of 
association between aspirin and warfarin dual therapy and increased prevalence of 
significant ICI should be interpreted with caution given the relatively small number of 
patients in this subgroups (n=42).
Our study did not collect data on DOACs, which limits the utility of our findings given that 
this class of medications has become increasingly common since the approval of dabigatran 
in 2008 in Europe and Canada, and 2010 in the United States (US).24 Use of DOACs has 
increased substantially in many European countries since approval, including in France, 
Germany, Austria, Belgium and the Netherlands, while use of warfarin has decreased.25–27 
Similar trends have been observed in the United States1,28 and in Alberta, Canada.29 
Rivaroxaban was the most commonly prescribed DOAC among patients in the US with atrial 
fibrillation in 2014, by which time DOACs were as commonly used as warfarin for this 
indication.1 More recent data demonstrate that DOACs have surpassed warfarin in both the 
US and the United Kingdom as the medication of choice to prevent thromboembolism.30,31 
However, as mentioned previously, clinical data suggests that the risk of intracranial 
bleeding among patients taking DOACs is likely similar to, and apparently no greater than 
the risk of bleeding among patients taking warfarin.22,23
Previous studies assessing the risk of post-traumatic bleeding have been limited by small 
sample sizes or retrospective design and their attendant biases. Jones et al. in a chart review 
of 43 patients on clopidogrel and 43 matched controls, found no significant difference in 
incidence of head injury, only a difference in rates of blood product administration.8 In 
another retrospective study looking at 35 patients on preinjury warfarin, compared to 
controls not on warfarin, Lavoie et al. found that anticoagulated patients had a higher 
prevalence of severe head injury and mortality.32 In a larger prospective study of over 1,000 
patients with blunt head trauma, Nishijima et al. found that the incidence of immediate 
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intracranial hemorrhage was higher among patients receiving clopidogrel as compared to 
those receiving warfarin (12.0% vs. 5.1%).33 The prevalence of significant ICI among 
patients on clopidogrel monotherapy was considerably lower in our study (2.6%) while the 
prevalence among those taking warfarin was similar (6.9%). However, Nishijima et al. did 
not enroll patients not taking any anticoagulant and antiplatelet medications, thus precluding 
any comparisons to patients without coagulopathy. The same group published a prospective, 
observational study enrolling over 1,300 older adults (>55 years) with and without 
anticoagulation or antiplatelet use and found that the incidence of traumatic intracranial 
hemorrhage (11%), after adjusted analysis, was not increased in those taking these 
medications.17 This study excluded patients under the age of 55 years, which could explain 
the higher incidence of traumatic intracranial hemorrhage via spectrum bias. Ganetsky et. al. 
studied a cohort of 939 patients with head trauma after ground level fall and found that the 
prevalence of traumatic intracranial hemorrhage was higher in the aspirin alone group 
(4.6%) than in the warfarin alone group (2.1%) with overlapping 95% confidence intervals. 
These findings are in contrast with our results, which showed a higher prevalence of 
significant ICI in the warfarin alone group. Again, Ganetsky et. al. did not enroll patients not 
taking any anticoagulant and antiplatelet medications, thus precluding any comparisons with 
patients without coagulopathy. Our multicenter study, with a large sample of prospectively 
collected data on patients with and without coagulopathy, may represent the largest and most 
rigorous attempt, to date, to determine the increased risk of significant ICI associated with 
these medications.
In summary, our prospective, observational study of adults presenting with blunt head 
trauma suggests that patients taking preinjury warfarin have a significantly increased risk of 
immediate significant ICI. An increased risk was also found among those taking a 
combination of aspirin and clopidogrel. Similar results were not found for those on preinjury 
aspirin alone or clopidogrel alone. Our results should be interpreted in the context of other 
prospective studies on this topic and should be confirmed in future studies. Since data on 
direct anticoagulants was not specifically collected, our study cannot shed light on the 
potentially increased risks of traumatic injury associated with these medications but the risk 
of intracranial injury is likely to be similar to, or at least no greater than, the risk associated 
with warfarin. Our study findings suggest that clinicians evaluating ED patients with blunt 
head trauma would be prudent in maintaining a low threshold for neuroimaging for those 
taking warfarin or a combination of aspirin and clopidogrel.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Grant Support:
This work was funded, in part, by the following grants: Agency for Health Care Research and Quality 
(www.ahrq.gov) HS09699, National Center for Injury Prevention and Control (https://www.cdc.gov/injury) 
CE001589, UC Center for Health Quality and Innovation (health.universityofcalifornia.edu/innovation-center) 
HL120466. Dr. Probst is supported by the National Heart, Lung, And Blood Institute of the NIH under Award 
Number K23HL132052.
Probst et al. Page 8
Ann Emerg Med. Author manuscript; available in PMC 2021 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
References
1. Barnes GD, Lucas E, Alexander GC, Goldberger ZD. National Trends in Ambulatory Oral 
Anticoagulant Use. Am J Med. 2015;128(12):1300–1305 e1302.4658248 [PubMed: 26144101] 
2. Kirley K, Qato DM, Kornfield R, Stafford RS, Alexander GC. National trends in oral anticoagulant 
use in the United States, 2007 to 2011. Circ Cardiovasc Qual Outcomes. 2012;5(5):615–621. 
[PubMed: 22949490] 
3. Kim K, Lee TA, Touchette DR, DiDomenico RJ, Ardati AK, Walton SM. Contemporary Trends in 
Oral Antiplatelet Agent Use in Patients Treated with Percutaneous Coronary Intervention for Acute 
Coronary Syndrome. J Manag Care Spec Pharm. 2017;23(1):57–63 [PubMed: 28025925] 
4. Karve S, Levine D, Seiber E, Nahata M, Balkrishnan R. Trends in Ambulatory Prescribing of 
Antiplatelet Therapy among US Ischemic Stroke Patients: 2000–2007. Adv Pharmacol Sci. 
2012;2012:846163. [PubMed: 23251145] 
5. Stuntz M, Bernstein B. Recent trends in the prevalence of low-dose aspirin use for primary and 
secondary prevention of cardiovascular disease in the United States, 2012–2015. Prev Med Rep. 
2017;5:183–186. [PubMed: 28070474] 
6. Chenoweth JA, Gaona SD, Faul M, Holmes JF, Nishijima DK, Sacramento County Prehospital 
Research C. Incidence of Delayed Intracranial Hemorrhage in Older Patients After Blunt Head 
Trauma. JAMA Surg. 2018.
7. Franko J, Kish KJ, O’Connell BG, Subramanian S, Yuschak JV. Advanced age and preinjury 
warfarin anticoagulation increase the risk of mortality after head trauma. J Trauma. 2006;61(1):107–
110 [PubMed: 16832256] 
8. Jones K, Sharp C, Mangram AJ, Dunn EL. The effects of preinjury clopidogrel use on older trauma 
patients with head injuries. Am J Surg. 2006;192(6):743–745 [PubMed: 17161086] 
9. Howard JL, 2nd, Cipolle MD, Horvat SA, et al. Preinjury warfarin worsens outcome in elderly 
patients who fall from standing. J Trauma. 2009;66(6):1518–1522; discussion 1523–1514 [PubMed: 
19509609] 
10. van den Brand CL, Tolido T, Rambach AH, Hunink MG, Patka P, Jellema K. Systematic Review 
and Meta-Analysis: Is Pre-Injury Antiplatelet Therapy Associated with Traumatic Intracranial 
Hemorrhage? J Neurotrauma. 2017;34(1):1–7 [PubMed: 26979949] 
11. Peck KA, Calvo RY, Schechter MS, et al. The impact of preinjury anticoagulants and prescription 
antiplatelet agents on outcomes in older patients with traumatic brain injury. J Trauma Acute Care 
Surg. 2014;76(2):431–436 [PubMed: 24458049] 
12. Jagoda AS, Bazarian JJ, Bruns JJ Jr., et al. Clinical policy: neuroimaging and decisionmaking in 
adult mild traumatic brain injury in the acute setting. Ann Emerg Med. 2008;52(6):714–748 
[PubMed: 19027497] 
13. Clinical NIfHa, Excellence. Head injury: assessment and early management. Clinical Guideline 
2014; https://www.nice.org.uk/guidance/cg176. Accessed May 31, 2018.
14. Stiell IG, Wells GA, Vandemheen K, et al. The Canadian CT Head Rule for patients with minor 
head injury. Lancet. 2001;357(9266):1391–1396 [PubMed: 11356436] 
15. Haydel MJ, Preston CA, Mills TJ, Luber S, Blaudeau E, DeBlieux PM. Indications for computed 
tomography in patients with minor head injury. N Engl J Med. 2000;343(2):100–105 [PubMed: 
10891517] 
16. Mower WR, Hoffman JR, Herbert M, et al. Developing a decision instrument to guide computed 
tomographic imaging of blunt head injury patients. J Trauma. 2005;59(4):954–959 [PubMed: 
16374287] 
17. Nishijima DK, Gaona SD, Waechter T, et al. The incidence of traumatic intracranial hemorrhage in 
head-injured older adults transported by EMS with and without anticoagulant or antiplatelet use. J 
Neurotrauma. 2017.
18. Ganetsky M, Lopez G, Coreanu T, et al. Risk of Intracranial Hemorrhage in Ground-level Fall 
With Antiplatelet or Anticoagulant Agents. Acad Emerg Med. 2017;24(10):1258–1266 [PubMed: 
28475282] 
19. Mower WR, Gupta M, Rodriguez R, Hendey GW. Validation of the sensitivity of the National 
Emergency X-Radiography Utilization Study (NEXUS) Head computed tomographic (CT) 
Probst et al. Page 9
Ann Emerg Med. Author manuscript; available in PMC 2021 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
decision instrument for selective imaging of blunt head injury patients: An observational study. 
PLoS Med. 2017;14(7):e1002313. [PubMed: 28700585] 
20. Mower WR, Hoffman JR, Herbert M, et al. Developing a clinical decision instrument to rule out 
intracranial injuries in patients with minor head trauma: methodology of the NEXUS II 
investigation. Ann Emerg Med. 2002;40(5):505–514 [PubMed: 12399794] 
21. Stiell IG LH, Vandemheen K. et al. Obtaining consensus for the definition of “clinically important” 
brain injury in the CCC Study Acad Emerg Med 2000;7:572
22. Yokoyama S, Tanaka Y, Nakagita K, Hosomi K, Takada M. Bleeding Risk of Warfarin and Direct 
Oral Anticoagulants in Younger Population: A Historical Cohort Study Using a Japanese Claims 
Database. Int J Med Sci. 2018;15(14):1686–1693. [PubMed: 30588192] 
23. Vinogradova Y, Coupland C, Hill T, Hippisley-Cox J. Risks and benefits of direct oral 
anticoagulants versus warfarin in a real world setting: cohort study in primary care. BMJ. 
2018;362:k2505 [PubMed: 29973392] 
24. Makam RCP, Hoaglin DC, McManus DD, et al. Efficacy and safety of direct oral anticoagulants 
approved for cardiovascular indications: Systematic review and meta-analysis. PLoS One. 
2018;13(5):e0197583. [PubMed: 29795629] 
25. de Jong LA, Koops M, Gout-Zwart JJ, et al. Trends in direct oral anticoagulant (DOAC) use: health 
benefits and patient preference. Neth J Med. 2018;76(10):426–430 [PubMed: 30569888] 
26. Schuh T, Reichardt B, Finsterer J, Stollberger C. Age-dependency of prescribing patterns of oral 
anticoagulant drugs in Austria during 2011–2014. J Thromb Thrombolysis. 2016;42(3):447–451 
[PubMed: 27221106] 
27. Huiart L, Ferdynus C, Renoux C, et al. Trends in initiation of direct oral anticoagulant therapies for 
atrial fibrillation in a national population-based cross-sectional study in the French health 
insurance databases. BMJ Open. 2018;8(3):e018180.
28. Wong SL, Marshall LZ, Lawson KA. Direct oral anticoagulant prescription trends, switching 
patterns, and adherence in Texas Medicaid. Am J Manag Care. 2018;24(8 Spec No):SP309–SP314 
[PubMed: 30020743] 
29. Yu AYX, Malo S, Svenson LW, Wilton SB, Hill MD. Temporal Trends in the Use and Comparative 
Effectiveness of Direct Oral Anticoagulant Agents Versus Warfarin for Nonvalvular Atrial 
Fibrillation: A Canadian Population-Based Study. J Am Heart Assoc. 2017;6(11).
30. Katz DF, Maddox TM, Turakhia M, et al. Contemporary Trends in Oral Anticoagulant Prescription 
in Atrial Fibrillation Patients at Low to Moderate Risk of Stroke After Guideline-Recommended 
Change in Use of the CHADS2 to the CHA2DS2-VASc Score for Thromboembolic Risk 
Assessment: Analysis From the National Cardiovascular Data Registry’s Outpatient Practice 
Innovation and Clinical Excellence Atrial Fibrillation Registry. Circ Cardiovasc Qual Outcomes. 
2017;10(5)
31. Loo SY, Dell’Aniello S, Huiart L, Renoux C. Trends in the prescription of novel oral 
anticoagulants in UK primary care. Br J Clin Pharmacol. 2017;83(9):2096–2106. [PubMed: 
28390065] 
32. Lavoie A, Ratte S, Clas D, et al. Preinjury warfarin use among elderly patients with closed head 
injuries in a trauma center. J Trauma. 2004;56(4):802–807 [PubMed: 15187746] 
33. Nishijima DK, Offerman SR, Ballard DW, et al. Immediate and delayed traumatic intracranial 
hemorrhage in patients with head trauma and preinjury warfarin or clopidogrel use. Ann Emerg 
Med. 2012;59(6):460–468 e461–467. [PubMed: 22626015] 
Probst et al. Page 10
Ann Emerg Med. Author manuscript; available in PMC 2021 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. 
Patient Flow Diagram
*“Unknown” indicates patients who had “unknown” status for all three medications.
”Other” includes patients on a combination of the anticoagulant/antiplatelet medications and 
patients with “Other Coagulopathy”. (These subjects were not included in the primary 
analysis.)
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Figure 2: 
Relative Risk of Significant Intracranial Injury by Coagulopathy ICI: Intracranial Injury.
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Table 1:
Characteristics of Patients Presenting to the Emergency Department with Blunt Head Trauma
Variable All Patients, 
N=9,070 N (%)
Aspirin Alone, 
n=635 n (%)
Clopidogrel Alone, 
n=109 n (%)
Warfarin Alone, 
n=406 n (%)
Combination of 
AC/AP medications 
n=173, n (%)
Age in years, Median 
(IQR)
54.8 (34.7–74.3) 81.0 (70.5–87.3) 81.3 (69.3–88.3) 80.0 (68.0–87.3) 80.7 (70.0–87.2)
Gender
-Female 3543 (39.1) 323 (50.9) 58 (53.2) 185 (45.6) 56 (32.4)
-Male 5505 (60.7) 312 (49.1) 51 (46.8) 219 (53.9) 117 (67.6)
-Unknown 22 (0.2) 0 (0.0) 0 (0.0) 2 (0.5) 0 (0.0)
Race/Ethnicity
-Black 949 (10.5) 40 (6.3) 3 (2.8) 24 (5.9) 7 (4.0)
-White 5520 (60.9) 467 (73.5) 75 (68.8) 308 (75.9) 125 (72.3)
-Hispanic 1325 (14.6) 30 (4.7) 9 (8.3) 22 (5.4) 9 (5.2)
-Asian 499 (5.5) 34 (5.4) 7 (6.4) 19 (4.7) 10 (5.8)
-Other 777 (8.5) 64 (10.1) 15 (13.7) 33 (8.0) 22 (12.7)
Significant ICI
-No 8538 (96.7) 605 (95.3) 106 (97.2) 378 (93.1) 161 (93.1)
-Yes 532 (5.9) 30 (4.7) 3 (2.8) 28 (6.9) 12 (6.9)
NSx intervention
-No
-Yes 8773 (96.7) 626 (98.6) 108 (99.1) 390 (96.1) 165 (95.4)
297 (3.3) 9 (1.4) 1 (0.9) 16 (3.9) 8 (4.6)
Dangerous Mechanism*
-No 3053 (33.7) 356 (56.1) 64 (58.7) 218 (53.7) 98 (56.6)
-Yes 5221 (57.6) 239 (37.6) 40 (36.7) 153 (37.7) 61 (35.3)
-Unknown 796(8.8) 40 (6.3) 5 (4.6) 35 (8.6) 14 (8.1)
GCS 15
-No 2041 (22.5) 99 (15.6) 18 (16.5) 60 (14.8) 21 (12.1)
-Yes 7029 (77.5) 536 (84.4) 91 (83.5) 346 (85.2) 152 (87.9)
Significant Vomiting
-No 8625 (95.1) 612 (96.4) 108 (99.1) 392 (96.6) 171 (98.8)
-Yes 354 (3.9) 22 (3.5) 1 (0.9) 13 (3.2) 2 (1.2)
-Unknown 91 (1.0) 1 (0.2) 0 (0.0) 1 (0.2) 0 (0.0)
Significant Comorbidity
-No 4418 (48.7) 289 (45.5) 18 (16.5) 54 (13.3) 23 (13.3)
-Yes 1754 (19.3) 263 (41.4) 61 (56.0) 250 (61.6) 126 (72.8)
-Unknown 2898 (32.0) 83 (13.1) 30 (27.5) 102 (25.1) 24 (13.8)
Signs of basilar/
depressed skull fracture
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Variable All Patients, 
N=9,070 N (%)
Aspirin Alone, 
n=635 n (%)
Clopidogrel Alone, 
n=109 n (%)
Warfarin Alone, 
n=406 n (%)
Combination of 
AC/AP medications 
n=173, n (%)
-No 8647 (95.3) 616 (97.0) 107 (98.2) 395 (97.3) 169 (97.7)
-Yes 299 (3.3) 13 (2.0) 0 (0.0) 7 (1.7) 3 (1.7)
-Unknown 124 (1.4) 6 (0.9) 2 (1.8) 4 (1.0) 1 (0.6)
Scalp Hematoma
-No 5963 (65.7) 371 (58.4) 59 (54.1) 259 (63.8) 106 (61.3)
-Yes 3043 (33.6) 257 (40.5) 48 (44.1) 144 (35.5) 67 (38.7)
-Unknown 64 (0.7) 7 (1.1) 2 (1.8) 3 (0.7) 0 (0.0)
Neurologic deficit
-No 7463 (82.3) 569 (89.6) 97 (89.0) 349 (86.0) 153 (88.4)
-Yes 1364 (15.0) 51 (8.0) 8 (7.3) 51 (12.6) 16 (9.2)
-Unknown 243 (2.7) 15 (2.4) 4 (3.7) 6 (1.5) 4 (2.3)
Abnormal level alertness
-No 6557 (72.3) 529 (83.3) 90 (82.6) 333 (82.0) 150 (86.7)
-Yes 2418 (26.7) 97 (15.3) 17 (15.6) 71 (17.5) 22 (12.7)
-Unknown 95 (1.0) 9 (1.4) 2 (1.8) 2 (0.5) 1 (0.6)
Abnormal behavior
-No 6982 (77.0) 551 (86.8) 94 (86.2) 351 (86.5) 155 (89.6)
-Yes 1924 (21.2) 75 (11.8) 10 (9.2) 50 (12.3) 16 (9.2)
-Unknown 164 (1.8) 9 (1.4) 5 (4.6) 5 (1.2) 2 (1.2)
Amnesia >30 min.
-No 6068 (66.9) 477 (75.1) 85 (78.0) 311 (76.6) 143 (82.7)
-Yes 1405 (15.5) 98 (15.4) 9 (8.3) 47 (11.6) 18 (10.4)
-Unknown 1597 (17.6) 60 (9.4) 15 (13.8) 48 (11.8) 12 (6.9)
AC: anticoagulant; AP: antiplatelet; SD: Standard Deviation; sICI: Significant Intracranial Injury; NSx: Neurosurgical; GCS: Glasgow Coma Scale; 
Dangerous Mechanism defined as pedestrian struck by motor vehicle, occupant ejected from motor vehicle, fall from height >3 feet or five stairs.
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Table 2.
Prevalence of Significant Intracranial Injury and Surgical Intervention by Coagulopathy1
Significant Intracranial Injury Neurosurgical Intervention
Type of 
Coagulopathy
Frequency 
Count
% Prevalence 
(95% CI)
Relative Risk 
(95%CI)
Frequency 
Count
% Prevalence 
(95% CI)
Relative Risk 
(95%CI)
No coagulopathy 210/5715 3.7 (3.2, 4.2) ref 85/5715 1.5 (1.2, 1.8) ref
Aspirin 
Monotherapy
30/635 4.7 (3.3, 6.6) 1.29 (0.88, 1.87) 9/635 1.4 (0.7, 2.5) 0.95 (0.48, 
1.88)
Clopidogrel 
Monotherapy
3/109 2.8 (0.7, 7.0) 0.75 (0.24, 2.3) 1/109 0.92 (0.1, 4.0) 0.62 (0.09, 
4.39)
Warfarin 
Monotherapy
28/406 6.9 (4.7, 9.6) 1.88 (1.3, 2.8) 16/406 3.9 (2.3, 6.1) 2.65 (1.57, 
4.48)
Aspirin + 
Clopidogrel
9/85 10.6 (5.7, 18.9) 2.88 (1.5, 5.4) 6/85 7.1 (3.3, 14.6) 4.75 (2.13, 
10.6)
Aspirin + Warfarin 2/42 4.8 (0.13, 15.8) 1.30 (0.33, 5.0) 2/42 4.8 (0.13, 15.8) 3.2 (0.81, 12.6)
SICI: Significant Intracranial Injury. NSx: Surgical Intervention CI: Confidence Interval. Ref: Reference group.
1
.
 Unknown treated as Missing data.
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Table 3.
Subgroup Analysis for significant Intracranial Injury and Neurosurgical Intervention by Coagulopathy
Subgroup No 
Coagulopathy - 
Frequency count 
and Prevalence 
(95%CI)
Aspirin- 
Alone 
Frequency 
count and 
Relative Risk 
(95%CI)
Clopidogrel- 
Alone 
Frequency 
count and 
Relative Risk 
(95%CI)
Warfarin- 
Alone 
Frequency 
count and 
Relative Risk 
(95%CI)
Aspirin and 
Clopidogrel 
Combination 
Frequency 
count and 
Relative Risk 
(95%CI)
Aspirin and 
Warfarin 
Combination 
Frequency 
count and 
Relative Risk 
(95%CI)
Significant Intracranial Injury
Patients 65 years or 
older
80/1307 23/537 3/90 23/323 8/74 2/38
6.1 0.70 0.5 1.2 1.8 0.86
(4.9, 7.5) (0.44, 1.1) (0.18, 1.7) (0.74, 1.8) (0.89, 3.5) (0.22, 3.4)
Patients with 
significant 
comorbidity
28/648 12/263 2/61 16/250 6/57 1/33
4.3 1.1 0.76 1.5 2.4 0.70
(2.9, 6.1) (0.55, 2.0) (0.19, 3.1) (0.82, 2.7) (1.05, 5.6) (0.1, 5.0)
Patients with 
dangerous 
mechanism
135/3585 14/239 2/40 15/153 3/33 1/15
3.8 1.6 1.3 2.6 2.4 1.77
(3.2, 4.4) (0.91, 2.6) (0.34, 5.2) (1.56, 4.3) (0.81, 7.2) (0.26, 11.8)
Patients with GCS of 
15
111/4783 19/536 2/91 19/346 7/70 1/60
2.3 1.5 0.95 2.4 4.3 1.1
(1.9, 2.8) (0.95, 2.5) (0.24, 3.8) (1.47, 3.8) (2.1, 8.9) (0.16, 7.7)
Patients normal level 
of alertness
104/4518 20/529 0/90 16/328 6/71 0/37
2.3 1.6 Non-Estimable 2.1 3.7 Non-Estimable
(1.9, 2.8) (1.0, 2.6) (1.3, 3.5) (1.7, 8.1)
Neurosurgical Intervention
Patients 65 years or 
older
36/1307 7/537 1/90 13/323 6/74 2/38
2.8 0.47 0.40 1.5 2.9 1.9
(2.0, 3.7) (0.21, 1.06) (0.06, 2.9) (0.78, 2.7) (1.28, 6.76) (0.48, 7.65)
Patients with 
significant 
comorbidity
12/648 4/263 1/61 8/250 3/57 1/33
1.9 0.82 0.89 1.7 2.8 1.6
(1.0, 3.1) (0.27, 2.5) (0.12, 6.7) (0.72, 4.2) (0.83, 9.78) (0.22, 12.21)
Patients with 
dangerous 
mechanism
52/3585 4/239 1/40 9/153 2/33 1/15
1.5 1.2 1.7 4.1 4.2 4.6
(1.1, 1.9) (0.42, 3.2) (0.24, 12.2) (2.0, 8.1) (1.06, 16.44) (0.68, 31.1)
Patients with GCS of 
15
30/4783 5/536 0/91 9/346 4/70 1/39
0.63 1.5 Non-Estimable 4.2 9.1 4.1
(0.4, 0.9) (0.58, 3.8) (1.98, 8.7) (3.3, 25.17) (0.57, 29.2)
Patients normal level 
of alertness
32/4518 5/529 0/90 5/328 4/71 0/37
0.71 1.3 Non-Estimable 3.4 8.0 Non-Estimable
(0.5–1.0) (0.52, 3.4) (0.84, 5.5) (2.89, 21.9)
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Table 4:
Prevalence of Any Traumatic Injury by Coagulopathy
Any Traumatic Injury
Type of Coagulopathy Frequency Count % Prevalence - Any Injury (95% CI) Relative Risk - Any Injury (95%CI)
No coagulopathy 459/5715 8.0 (7.4, 8.8) Ref
Aspirin Monotherapy 55/635 8.7 (6.7, 11.1) 1.08 (0.82, 1.41)
Clopidogrel Monotherapy 10/109 9.2 (5.1, 16) 1.14 (0.63, 2.08)
Warfarin Monotherapy 48/406 12 (9.0, 15) 1.49 (1.13, 1.97)
Aspirin + Clopidogrel 14/85 16 (10, 26) 2.05 (1.26, 3.34)
Aspirin + Warfarin 7/42 17 (8.3, 31) 2.08 (1.05, 4.10)
CI: Confidence Interval.
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